RA CAPITAL MANAGEMENT, L.P.
Institutional investor · Portfolio as of Q3 2019
Top Holdings32 positions
Stock | Shares | Value | Weight | Avg Buy | Est. P&L | Held | Conviction |
|---|---|---|---|---|---|---|---|
ASCENDIS PHARMA A/S | 4.1M | $398M | 23.7% | $59.89 | +60.61% | 4 qtrssince 2018-Q4 | Unchanged 0 |
WAVE LIFE SCIENCES LTD | 7.8M | $159.6M | 9.5% | $42.17 | -51.70% | 4 qtrssince 2018-Q4 | Unchanged 0 |
Synthorx Inc | 9.7M | $158.2M | 9.4% | — | — | 4 qtrssince 2018-Q4 | Unchanged 0 |
RA PHARMACEUTICALS INC | 4.9M | $114.9M | 6.8% | — | — | 4 qtrssince 2018-Q4 | Unchanged 0 |
ZOGENIX INC | 2.3M | $90.5M | 5.4% | — | — | 4 qtrssince 2018-Q4 | Decreased 0 |
EIDOS THERAPEUTICS INC | 2.2M | $77.8M | 4.6% | — | — | 4 qtrssince 2018-Q4 | Unchanged 0 |
RHYTHM PHARMACEUTICALS INC | 3.4M | $73.9M | 4.4% | $24.41 | -13.18% | 4 qtrssince 2018-Q4 | Increased 85 |
SATSUMA PHARMACEUTICALS INC | 4.7M | $70.3M | 4.2% | — | — | 1 qtr | New 83 |
ORCHARD THERAPEUTICS PLC | 5.2M | $62.1M | 3.7% | — | — | — | — |
| 4.6M | $47.3M | 2.8% | — | — | 4 qtrssince 2018-Q4 | Increased 75 | |
| 4M | $46.2M | 2.8% | — | — | — | New 77 | |
PREVAIL THERAPEUTICS INC | 3.4M | $41.3M | 2.5% | — | — | 2 qtrssince 2019-Q2 | Increased 61 |
TG Therapeutics, Inc. | 6.9M | $38.6M | 2.3% | $3.98 | +41.96% | 4 qtrssince 2018-Q4 | Unchanged 0 |
ARVINAS INC | 1.7M | $35.8M | 2.1% | $13.16 | +72.87% | 4 qtrssince 2018-Q4 | Decreased 0 |
DICERNA PHARMACEUTICALS INC | 2.5M | $35.3M | 2.1% | — | — | 4 qtrssince 2018-Q4 | Unchanged 0 |
MYOVANT SCIENCES LTD | 6.2M | $32.1M | 1.9% | — | — | 4 qtrssince 2018-Q4 | Decreased 0 |
CRINETICS PHARMACEUTICALS IN | 1.9M | $28.2M | 1.7% | $30.51 | -50.41% | 4 qtrssince 2018-Q4 | Unchanged 0 |
STOKE THERAPEUTICS INC | 1.1M | $24.1M | 1.4% | $29.17 | -29.62% | 2 qtrssince 2019-Q2 | Unchanged 0 |
SCPHARMACEUTICALS INC | 3.2M | $19.1M | 1.1% | — | — | 4 qtrssince 2018-Q4 | Unchanged 0 |
KALA BIO, Inc. | 4.5M | $17.3M | 1.0% | — | — | — | — |
RA CAPITAL MANAGEMENT, L.P. manages $1.7B across 32 positions as of Q3 2019. Top holdings: ASND (23.7%), WVE (9.5%), THOR (9.4%). Fund DNA: Balanced Allocator. HoldingsIntel Rating: 3/5.0.
Active quarter - 9 new positions, 2 exits, 4 increased. Top move: RYTM (INCREASED, conviction 85). Portfolio: $1.7B across 32 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer